The shingles jab and your heart: what new research found
What happened
New research suggests the modern shingles vaccine may do more than prevent shingles. It may also be linked to less heart disease. The study was published in the journal Nature Medicine on 26 August 2026. It compared what happened to people who had the older live shingles vaccine with people who had the newer recombinant vaccine, sold as Shingrix. The people who received the recombinant vaccine had a 9 per cent lower burden of cardiovascular disease. Cardiovascular disease is the umbrella term for problems with the heart and blood vessels, including heart attacks and strokes. On 4 September 2026, The Pharmaceutical Journal reported that the finding had prompted a call for change. The Independent Pharmacies Association (IPA) urged the government to speed up its plans to widen who can have the vaccine. At the moment, the NHS plan is gradual. Eligibility is due to widen to people aged 60 in September 2028, and the vaccine is not due to become a routine offer for everyone aged 60 and over until September 2033. The IPA's chief executive, Leyla Hannbeck, argued that waiting until 2033 would leave millions of people without potentially life-changing protection for years longer than necessary. The research was also discussed by Mark Russell, a clinical senior lecturer and consultant rheumatologist at King's College London. Shingrix is made by GSK. Decisions about who the NHS offers vaccines to are made on the advice of the Joint Committee on Vaccination and Immunisation, known as the JCVI.
Why this matters
Shingles is worth avoiding in its own right. It is caused by the same virus that causes chickenpox. Once you have had chickenpox, the virus does not leave. It sits quietly in your nerves, sometimes for sixty or seventy years. If it wakes up, it causes shingles: a painful, blistering rash, usually in a band on one side of the body. Most people recover. But a minority are left with nerve pain that carries on for months or even years after the rash has gone. It can be severe. It can stop people sleeping, working and going out. So a vaccine that prevents that is already valuable. If it also turns out to be linked to fewer heart attacks and strokes, that changes the sums considerably. Heart and circulatory disease is one of the biggest causes of death in the UK. A 9 per cent difference in the burden of that disease, spread across a whole population of older adults, is not a small thing. That is the argument the IPA is making. If the benefit is real and it is broader than we thought, then a rollout timetable stretching to 2033 starts to look slow.
What the evidence actually says
It is worth being careful here, because 'vaccine linked to lower heart disease' is exactly the kind of headline that runs ahead of the science. A few things to hold onto. First, the study compared two vaccines against each other. It looked at people who had the older live vaccine and people who had the newer recombinant one. That is a useful comparison, but it is not the same as comparing vaccinated people with unvaccinated people. Second, 9 per cent is a real but modest difference. It is not a claim that the jab prevents 9 per cent of heart attacks in the general population. Third, there is a plausible reason why this might happen, which makes the finding easier to believe. Shingles causes inflammation in and around blood vessels, and infections in general are known to raise the short-term risk of heart attacks and strokes. Preventing the infection may prevent some of that knock-on damage. But 'plausible' is not the same as 'proven'. Fourth, the decision about who gets an NHS vaccine is not made on one study. The JCVI weighs up how well a vaccine works, how long protection lasts, how many doses are needed, supply, and cost. That is deliberately slow and deliberately cautious, and it is why the UK vaccination programme is trusted. What is fair to say is this: the evidence for the recombinant shingles vaccine keeps getting stronger, and there is now a serious professional argument for moving faster.
Qurexa perspective
This one sits very close to what we do. We work with people who are managing long-term conditions and taking regular medicines, and a good number of them are in exactly the age groups the shingles programme covers. In our experience, the biggest barrier to being vaccinated is almost never refusal. It is that nobody got round to it. The letter arrives during a busy week. The appointment clashes with something. Six months pass. If you are eligible now, the single most useful thing you can do is book it now rather than wait for the debate about 2028 or 2033 to be settled. Your GP surgery will invite you when you become eligible, and many community pharmacies can help you work out where you stand. And if you are supporting an older relative, this is a good one to help with. Offering to make the call is often the whole difference.
Practical advice
**Find out if you are eligible.** The NHS shingles vaccine is offered by age, and separately to some people with a weakened immune system. Rather than guessing, ring your GP surgery and ask directly whether you are eligible yet. It is a two-minute call. **Take the second dose.** The recombinant vaccine is given as two doses. One dose is not the full course. If you have had the first and not the second, that is worth sorting out now. **Do not buy on the strength of a headline.** If you are not yet eligible on the NHS, the vaccine is available privately at some pharmacies. That may be a reasonable choice for some people, but talk it through with a pharmacist first rather than deciding from a news story. **Know the early signs of shingles.** It often starts with a burning, tingling or painful patch of skin on one side of the body, a day or two before any rash appears. If you think you have shingles, contact your GP or NHS 111 quickly. Antiviral treatment works best when it is started within about 72 hours of the rash starting. **Look after the heart risks you can already control.** Whatever this research eventually shows, blood pressure, cholesterol, smoking and activity remain the things with the strongest evidence behind them.
What to know
Research in Nature Medicine has linked the recombinant shingles vaccine to a 9 per cent lower burden of cardiovascular disease compared with the older live vaccine. Pharmacy leaders have used the finding to argue that the NHS should widen access sooner than the current timetable of 2028 and 2033. Nothing about NHS eligibility has changed yet. What has changed is the strength of the case. If you are already eligible, the sensible move is to have the vaccine, and to complete both doses. Sources: The Pharmaceutical Journal, 'Call to expand shingles vaccine following cardiovascular research', 4 September 2026, https://pharmaceutical-journal.com/article/news/call-to-expand-shingles-vaccine-following-cardiovascular-research | Nature Medicine, study comparing cardiovascular outcomes after live and recombinant zoster vaccination, 26 August 2026, https://www.nature.com/nm/ | NHS, 'Shingles vaccine', https://www.nhs.uk/vaccinations/shingles-vaccine/ This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.
Related articles
Free finger-prick kits that tell you your blood type
NHS Blood and Transplant has started giving away free kits that let you find out your own blood type at home. The scheme was announced on 2 September 2026. Up…
A common prostate and ED medicine is linked to higher glaucoma risk
A large study has linked long-term use of the medicine tadalafil to a higher chance of developing glaucoma, an eye condition that can steal your sight without w…